However, as CD47 is widely expressed on the surface of a broad range of cell types, including erythrocytes and platelets, a major limitation of CD47 blocking agents is the target-mediated drug disposition and the potential side effects, which include anaemia or thrombocytopenia. Here, CD47 is linked to anemia.